Diabetes experts' reasoning about diabetes prevention studies: A questionnaire survey

BMC Research Notes

Volumn 1, Issue , 2008, Pages

  Mühlhauser, Ingrid ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 68149108977     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-1-90     Document Type: Article

References (22)

1. Understanding of diabetes prevention studies: questionnaire survey of professionals in diabetes care. I Mühlhauser J Kasper G Meyer FEND, Diabetologia 2006 49 1742 1746 10.1007/s00125-006-0290-8 16718464
2. Presenting risk information a review of the effects of "framing" and other manipulation on patient outcomes. A Edwards G Elwyn J Covey E Matthews R Pill, J Health Commun 2001 6 61 82 10.1080/10810730150501413 11317424
3. Absolutely relative: how research results are summarized can affect treatment decisions. L Forrow WC Taylor RM Arnold, Am J Med 1992 92 121 124 10.1016/0002-9343(92)90100-P 1543193
4. Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. HC Bucher M Weinbacher K Gyr, BMJ 1994 309 761 764 7950558
5. Communicating statistical information. U Hoffrage S Lindsey R Hertwig G Gigerenzer, Science 2000 290 2261 2262 10.1126/science.290.5500.2261 11188724
6. Different ways to describe the benefits of risk-reducing treatments. A randomized trial. PA Halvorsen R Selmer IS Kristiansen, Ann Intern Med 2007 146 848 856 17577004
7. Evidence based purchasing: understanding results of clinical trials and systematic reviews. T Fahey S Griffiths TJ Peters, BMJ 1995 311 1056 1060 7580661
8. The arrogance of preventive medicine. DL Sackett, CMAJ 2002 167 363 364 12197692
9. Straight talk about disease prevention. HC Sox, Ann Intern Med 2007 146 891 892 17577010
10. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group, Lancet 1998 352 837 853 10.1016/S0140-6736(05)61359-1 9742976
11. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. J Tuomilehto J Lindström J-G Eriksson TT Valle H Hämäläinen P Ilanne-Parikka S Keinänen-Kiukaanniemi M Laakso A Louheranta M Rastas V Salminen M Uusitupa Finnish Diabetes Prevention Study Group, NEJM 2001 344 1343 1350 10.1056/NEJM200105033441801 11333990 (Pubitemid 32378388)
12. The Finnish diabetes prevention study (DPS). J Lindström A Louheranta M Mannelin M Rastas V Salminen J Eriksson M Uusitupa J Tuomilehto Finnish Diabetes Prevention Study Group, Diabetes Care 2003 26 3230 3236 10.2337/diacare.26.12.3230 14633807
13. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group, NEJM 2002 346 393 403 11832527 10.1056/NEJMoa012512 (Pubitemid 34437694)
14. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. DM Eddy L Schlessinger R Kahn, Ann Intern Med 2005 143 251 264 16103469
15. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. J-L Chiasson RG Josse R Gomis M Hanefeld A Karasik M Laakso for The STOP-NIDDM Trial Research Group, Lancet 2002 359 2072 2077 10.1016/S0140-6736(02)08905-5 12086760
16. Acarbose for type 2 diabetes prevention. I Mühlhauser, Lancet 2002 360 517 10.1016/S0140-6736(02)11458-9
17. Glucose lowering and diabetes prevention: are they the same? J Tuomilehto N Wareham, Lancet 2006 368 1218 1219 10.1016/S0140-6736(06)69421-X 17027710
18. Retinopathy, plasma glucose, and the diagnosis of diabetes. M Quresh A Evans, Lancet 2008 371 700 702 10.1016/S0140-6736(08)60318-9 18313485
19. Prevention of Type II diabetes in subjects with impaired glucose tolerance: the Diabetes Prevention Study (DPS) in Finland. Study design and 1-year interim report on the feasibility of the lifestyle intervention programme. J Eriksson J Lindström T Valle S Aunola H Hämälä inen P Ilanne-Parikka S Keinänen-Kiukaanniemi M Laakso M Lauhkonen P Lehto A Lehtonen A Louheranta M Mannelin V Martikkala M Rastas J Sundvall A Turpeinen T Viljanen M Uusitupa J Tuomilehto, Diabetologia 1999 42 793 801 10.1007/s001250051229 10440120
20. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. J Lindström P Ilanne-Parikka M Peltonen S Aunola JG Eriksson K Hemiö H Hämäläinen P Härkönen S Keinänen-Kiukaanniemi M Laakso A Louheranta M Mannelin M Paturi J Sundvall TT Valle M Uusitupa J Tuomilehto Finnish Diabetes Prevention Study Group, Lancet 2006 368 1673 1779 10.1016/S0140-6736(06)69701-8 17098085
21. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. CL Gillies KR Abrams PC Lambert NJ Cooper AJ Sutton RT Hsu K Khunti, BMJ 2007 334 299 17237299 10.1136/bmj.39063.689375.55 (Pubitemid 46293963)
22. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and surveys of authors. AW Chan DG Altman, BMJ 2005 330 753 756 15681569 10.1136/bmj.38356.424606.8F